Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
AssigneeISA Pharmaceuticals B.V.
InventorsWilhelmus Johannes Theodorus Alexander KREBBER, Johan Herman KESSLER, Cornelis Joseph Maria MELIEF, Kitty Michelle Corinne KWAPPENBERG
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
Claims16
-15. (canceled)
A peptide comprising at least 70 predicted HLA class I-restricted CD8+ cytotoxic T-cell epitopes, at least 1 predicted HLA class II-restricted CD4+ T-helper epitope, and at least 3 proteasomal cleavage sites, wherein the peptide is derived from an HBV protein and wherein the peptide is at most 40 amino acids in length and comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 75, 51-74, 76-79, 1142-1145 and 1468-1471.
Dependencies are inferred from the claim text.